|2.40||-0.145 / -5.71%|
As of 3:59pm ET
|2.34||-0.055 / -2.30%|
The 3 analysts offering 12-month price forecasts for Repros Therapeutics Inc have a median target of 2.00, with a high estimate of 4.50 and a low estimate of 2.00. The median estimate represents a -16.49% decrease from the last price of 2.40.
The current consensus among 5 polled investment analysts is to Hold stock in Repros Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.